DE602005009954D1 - Nukleinsäure-mikrokügelchen, ihre herstellung und abgabe - Google Patents

Nukleinsäure-mikrokügelchen, ihre herstellung und abgabe

Info

Publication number
DE602005009954D1
DE602005009954D1 DE602005009954T DE602005009954T DE602005009954D1 DE 602005009954 D1 DE602005009954 D1 DE 602005009954D1 DE 602005009954 T DE602005009954 T DE 602005009954T DE 602005009954 T DE602005009954 T DE 602005009954T DE 602005009954 D1 DE602005009954 D1 DE 602005009954D1
Authority
DE
Germany
Prior art keywords
delivery
manufacture
nucleic acid
micro beads
nucleic acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005009954T
Other languages
English (en)
Inventor
Terrence L Scott
Debra Lafreniere
Vered Bisker-Leib
Larry R Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Publication of DE602005009954D1 publication Critical patent/DE602005009954D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
DE602005009954T 2004-05-12 2005-05-12 Nukleinsäure-mikrokügelchen, ihre herstellung und abgabe Active DE602005009954D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57027304P 2004-05-12 2004-05-12
US62531104P 2004-11-05 2004-11-05
PCT/US2005/016660 WO2005112894A1 (en) 2004-05-12 2005-05-12 Nucleic acid microspheres, production and delivery thereof

Publications (1)

Publication Number Publication Date
DE602005009954D1 true DE602005009954D1 (de) 2008-11-06

Family

ID=34969601

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005009954T Active DE602005009954D1 (de) 2004-05-12 2005-05-12 Nukleinsäure-mikrokügelchen, ihre herstellung und abgabe

Country Status (12)

Country Link
US (2) US7815941B2 (de)
EP (3) EP2335689A1 (de)
JP (2) JP2007537284A (de)
AT (1) ATE409025T1 (de)
AU (1) AU2005244842B2 (de)
CA (1) CA2566079A1 (de)
DE (1) DE602005009954D1 (de)
DK (2) DK1765294T3 (de)
ES (2) ES2313350T3 (de)
MX (1) MXPA06012990A (de)
PT (1) PT1765294E (de)
WO (1) WO2005112894A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
ATE409025T1 (de) * 2004-05-12 2008-10-15 Baxter Int Nukleinsäure-mikrokügelchen, ihre herstellung und abgabe
MXPA06012989A (es) 2004-05-12 2007-06-12 Baxter Int Microesferas de acidos nucleicos, produccion y suministro de las mismas.
US8728525B2 (en) * 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
EP1885335A1 (de) * 2005-04-27 2008-02-13 BAXTER INTERNATIONAL INC. (a Delaware corporation) Oberflächenmodifizierte mikroteilchen und verfahren zu ihrer bildung und verwendung
US20070281031A1 (en) * 2006-06-01 2007-12-06 Guohan Yang Microparticles and methods for production thereof
EP2647712A3 (de) * 2006-08-04 2013-11-20 Baxter International Inc Zusammensetzung auf Mikrokügelchenbasis zur Vorbeugung und/oder Umkehrung einer Neuerkrankung an autoimmun bedingter Diabetes
AU2013213750B2 (en) * 2006-08-04 2013-09-26 Baxter Healthcare S.A. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
AU2007319577A1 (en) * 2006-10-06 2008-05-22 Baxter Healthcare S.A. Microencapsules containing surface-modified microparticles and methods of forming and using the same
AU2008242842B2 (en) * 2007-04-17 2014-06-05 Baxter Healthcare Sa Nucleic acid microparticles for pulmonary delivery
JP5685182B2 (ja) * 2008-04-18 2015-03-18 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 初発自己免疫性糖尿病を予防するため、および／または逆転させるためのマイクロスフェアに基づく組成物
US8936811B2 (en) 2008-05-07 2015-01-20 Surmodics, Inc. Device coated with glycogen particles comprising nucleic acid complexes
US8323685B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8367427B2 (en) * 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US20100047292A1 (en) * 2008-08-20 2010-02-25 Baxter International Inc. Methods of processing microparticles and compositions produced thereby
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP4108671A1 (de) 2010-10-01 2022-12-28 ModernaTX, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und ihre verwendungen
US8901092B2 (en) 2010-12-29 2014-12-02 Surmodics, Inc. Functionalized polysaccharides for active agent delivery
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN103974724B (zh) 2011-10-03 2019-08-30 现代泰克斯公司 修饰的核苷、核苷酸和核酸及其用途
CA2859387A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243951A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
JP6144355B2 (ja) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 化学修飾ｍＲＮＡ
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048395A1 (en) * 2013-09-26 2015-04-02 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Tolerogenic dendritic cells to treat inflammatory bowel disease
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
CN116064746A (zh) * 2022-09-16 2023-05-05 上海伯杰医疗科技股份有限公司 用于核酸扩增的微球制剂、扩增方法及在联合检测中的应用

Family Cites Families (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2010115A1 (de) 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
US3726268A (en) * 1971-05-03 1973-04-10 R Stansell Cooking apparatus
BE786675A (fr) * 1971-08-02 1973-01-25 Airco Inc Separation d'oxydes d'alkyle halogenes par distillation azeotropique.
US3846332A (en) 1971-08-02 1974-11-05 Airco Inc Azeotropes of 1-chloro-2,2,2-trifluoroethyl difluoromethyl ether with acetone, methyl ethylketone and tetrahydrofuran
US3897502A (en) * 1971-10-22 1975-07-29 Airco Inc Process for making fluorinated ethers
JPS523342B2 (de) 1972-01-26 1977-01-27
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4818542A (en) 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4584894A (en) 1984-02-29 1986-04-29 Borg-Warner Corporation Transmission anti-clash and anti-rattle brake
US5417986A (en) 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
ATE61935T1 (de) 1985-02-07 1991-04-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US5102872A (en) 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
GB8601100D0 (en) 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
EP0248531A3 (de) 1986-05-02 1988-09-28 Southern Research Institute Verkapselte Nukleinsäuren
KR950014440B1 (ko) 1986-08-11 1995-11-28 이노바타 바이오메드 리미티드 마이크로캡슐을 포함하는 제약학적 배합물
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4762856A (en) * 1987-02-02 1988-08-09 Boc, Inc. Anesthetic composition and method of using the same
US4861627A (en) 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US4874901A (en) 1988-05-06 1989-10-17 Boc, Inc. Process for the production of polyfluorinated ethers
US5015781A (en) * 1988-05-06 1991-05-14 Boc, Inc. Anesthetic compound and method of preparing
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
US4855511A (en) * 1988-07-18 1989-08-08 Boc, Inc. Process for preparing CHF2 OCHFCF3 and CHF2 OCHClCF3 and novel intermediate compounds employed therein
US4972040A (en) 1988-07-18 1990-11-20 Boc, Inc. Process for the preparation of CHF2 OCHFCF3
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
USRE39497E1 (en) 1989-02-16 2007-02-27 Nektar Therapeutics Storage of materials
US5026924A (en) * 1989-03-14 1991-06-25 Anaquest, Inc. Process for production of 1,2,2,2-tetrafluoroethyl difluoromethyl ether
DE69024953T3 (de) 1989-05-04 2005-01-27 Southern Research Institute, Birmingham Einkapselungsverfahren
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
JP3359919B2 (ja) 1990-05-16 2002-12-24 サザン・リサーチ・インスティテュート 放出制御ドーパミンおよび神経線維成長を刺激するための用途
JPH0436233A (ja) * 1990-05-29 1992-02-06 Biomaterial Universe Kk 生理活性物質含有生体内分解吸収性の徐放性製剤
GB9016885D0 (en) 1990-08-01 1990-09-12 Scras Sustained release pharmaceutical compositions
US5149543A (en) 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
GB9023370D0 (en) * 1990-10-26 1990-12-05 Rhone Poulenc Chemicals Synthesis of fluorinated substituted ethanes
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
AU1442592A (en) 1991-02-20 1992-09-15 Nova Pharmaceutical Corporation Controlled release microparticulate delivery system for proteins
US5330768A (en) 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
US6063910A (en) 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
US5283372A (en) * 1991-12-04 1994-02-01 Anaquest, Inc. Preparation of purified optical isomers of desflurane
US5525519A (en) 1992-01-07 1996-06-11 Middlesex Sciences, Inc. Method for isolating biomolecules from a biological sample with linear polymers
US5173454A (en) 1992-01-09 1992-12-22 Corning Incorporated Nanocrystalline materials
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
DE4211169C1 (de) 1992-03-31 1993-06-03 Klaus Kretzschmar
JP2651320B2 (ja) 1992-07-16 1997-09-10 田辺製薬株式会社 徐放性マイクロスフェア製剤の製造方法
US5205914A (en) * 1992-08-14 1993-04-27 Anaquest, Inc. Synthesis of desflurane
JP3277342B2 (ja) 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
EP0595030A3 (de) 1992-10-01 1995-06-07 Tanabe Seiyaku Co Mehrkern-Mikrosphären mit verzögerter Wirkstoffabgabe und Verfahren zu deren Herstellung.
EP0674506B1 (de) 1992-12-02 2000-08-23 Alkermes Controlled Therapeutics, Inc. Wachstumhormon enthaltende mikrosphaeren mit kontrollierter freisetzung
WO1994018947A1 (en) * 1993-02-16 1994-09-01 Sharifa Karali High purity protamine-dna complex and use of same
US5578709A (en) 1993-03-09 1996-11-26 Middlesex Sciences, Inc. Macromolecular microparticles and methods of production
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5994314A (en) 1993-04-07 1999-11-30 Inhale Therapeutic Systems, Inc. Compositions and methods for nucleic acid delivery to the lung
TW404844B (en) 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5932248A (en) 1993-11-18 1999-08-03 Paragon Medical Limited Controlled release preparations for cytotoxic or cytostatic drugs
EP2283821A1 (de) 1993-11-19 2011-02-16 Alkermes, Inc. Herstellung biodegradierbarer Mikroteilchen, die ein biologisch aktives Mittel enthalten
US5650173A (en) 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
US5858973A (en) 1994-02-23 1999-01-12 The General Hospital Corporation Transcription factor and uses therefor
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
WO1996003978A1 (en) 1994-08-04 1996-02-15 Quadrant Holdings Cambridge Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US5542920A (en) 1994-09-12 1996-08-06 Delab Needle-less parenteral introduction device
US6387399B1 (en) 1994-12-02 2002-05-14 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Microencapsulated bioactive agents and method of making
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
SE505146C2 (sv) 1995-10-19 1997-06-30 Biogram Ab Partiklar för fördröjd frisättning
US5665428A (en) 1995-10-25 1997-09-09 Macromed, Inc. Preparation of peptide containing biodegradable microspheres by melt process
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
US5958769A (en) * 1996-01-18 1999-09-28 Fred Hutchinson Cancer Research Center Compositions and methods for mediating cell cycle progression
GB9607035D0 (en) 1996-04-03 1996-06-05 Andaris Ltd Spray-dried microparticles as therapeutic vehicles
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
WO1998001162A2 (en) 1996-07-09 1998-01-15 The Johns Hopkins University Gene delivery system
US6395302B1 (en) 1996-11-19 2002-05-28 Octoplus B.V. Method for the preparation of microspheres which contain colloidal systems
US6319906B1 (en) 1996-12-31 2001-11-20 Isis Pharmaceuticals Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6077833A (en) 1996-12-31 2000-06-20 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
US5945126A (en) 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
EP0975334B1 (de) 1997-04-17 2003-10-22 Amgen Inc., Bioabbaubare mikropartikeln mit verzögerter wirkstofffreisetzung
JP2002508765A (ja) * 1997-06-23 2002-03-19 アルザ コーポレイション リポソーム被包ポリヌクレオチド組成物および方法
IL134084A0 (en) 1997-07-18 2001-04-30 Infimed Inc Biodegradable macromers for the controlled release of biologically active substances
US6042792A (en) * 1997-09-18 2000-03-28 International Flavors & Fragrances Inc. Apparatus for preparing a solid phase microparticulate composition
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
CA2318493A1 (en) * 1998-01-16 1999-07-22 The Johns Hopkins University Oral delivery of nucleic acid vaccines by particulate complexes
US20040186071A1 (en) 1998-04-13 2004-09-23 Bennett C. Frank Antisense modulation of CD40 expression
US6395253B2 (en) 1998-04-23 2002-05-28 The Regents Of The University Of Michigan Microspheres containing condensed polyanionic bioactive agents and methods for their production
US6197584B1 (en) 1998-05-01 2001-03-06 Isis Pharmaceuticals, Inc. Antisense modulation of CD40 expression
ATE324913T1 (de) 1998-08-14 2006-06-15 Valentis Inc Co-lyophilisierter komplex umfassend einen nukleinsäurevektor und ein formulierungsagens
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
WO2000041679A1 (en) * 1999-01-13 2000-07-20 Johns Hopkins University School Of Medicine Genetic immunization with co-delivery of nucleic acid and cytokines
GB9904627D0 (en) * 1999-03-02 1999-04-21 Danbiosyst Uk Polymer compositions for polynucleotide delivery
US6630169B1 (en) 1999-03-31 2003-10-07 Nektar Therapeutics Particulate delivery systems and methods of use
EP1173151B1 (de) 1999-04-16 2003-07-09 Novo Nordisk A/S Trockene formbare arzneistoffformulierung
EP1046651A1 (de) * 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Zusammensetzungen und Verfahren zur Modulierung des interaktion zwischen dendritischer und T-zellen
CA2373016A1 (en) 1999-05-04 2000-11-09 Genethor Gmbh Method for diminishing specific immune reactions
ES2207123T3 (es) 1999-06-14 2004-05-16 Baxter International Inc. Microesferas de liberacion sostenida.
EP1194128A2 (de) 1999-06-23 2002-04-10 Sedum Laboratories Ionisch formulierte mikroträger für biomoleküle
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
FR2809309B1 (fr) 2000-05-23 2004-06-11 Mainelab Microspheres a liberation prolongee pour administration injectable
DK1283720T3 (da) 2000-05-26 2007-08-13 Symphogen As Rekombinante eller rensede polyklonale antistoffer til behandling af allergi
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
KR100392501B1 (ko) 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
US6471995B1 (en) 2000-09-27 2002-10-29 Alkermes Controlled Therapeutics, Inc. Ii Apparatus and method for preparing microparticles using liquid-liquid extraction
CA2423227C (en) 2000-10-12 2011-11-29 Genentech, Inc. Reduced-viscosity concentrated protein formulations
SE518007C2 (sv) 2000-11-16 2002-08-13 Bioglan Ab Förfarande för framställning av mikropartiklar
IL156618A0 (en) 2000-12-28 2004-01-04 Altus Biologics Inc Crystals of whole antibodies and fragments thereof, methods for the preparation thereof and diagnostic kits utilizing the same
EP1801123A3 (de) 2000-12-28 2007-11-21 Altus Pharmaceuticals Inc. Kristalle von ganzen Antikörpern und Fragmenten davon und Verfahren zu ihrer Herstellung und Verwendung
US6896905B2 (en) 2001-02-15 2005-05-24 Rohm And Haas Company Porous particles, their aqueous dispersions, and method of preparation
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CA2451185A1 (en) 2001-06-21 2003-01-03 Altus Biologics, Inc. Spherical protein particles and methods of making and using them
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
US20030064033A1 (en) 2001-08-16 2003-04-03 Brown Larry R. Propellant-based microparticle formulations
GB0207440D0 (en) * 2002-03-28 2002-05-08 Ppl Therapeutics Scotland Ltd Tolerogenic antigen-presenting cells
US20030224055A1 (en) 2002-05-28 2003-12-04 Lewis David L. Compositions and processes for inhibiting gene expression using polynucleotides
US6900998B2 (en) 2002-05-31 2005-05-31 Midwest Research Institute Variable-speed wind power system with improved energy capture via multilevel conversion
CN1671741A (zh) 2002-06-21 2005-09-21 拜奥根Idec公司 浓缩抗体的缓冲剂制剂及其使用方法
US20040014698A1 (en) 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
KR20100107083A (ko) 2002-12-17 2010-10-04 메디뮨 엘엘씨 생물활성 물질의 고압 분무 건조
US20060002862A1 (en) 2002-12-17 2006-01-05 Medimmune Vaccines, Inc. High pressure spray-dry of bioactive materials
US20050053666A1 (en) 2002-12-31 2005-03-10 Stelios Tzannis Antibody-containing particles and compositions
KR101208291B1 (ko) 2003-04-04 2012-12-05 노파르티스 아게 고농도 항체 및 단백질 제형
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
ES2216707B1 (es) 2003-04-08 2005-12-16 Josep Maria Aran Perramon Secuencia oligoribonucleotidica homologa a una region del cdna que codifica para el receptor cd40 humano y oligoribonucleotidos duplex, vectores, composiciones farmaceuticas y usos correspondientes.
US7723311B2 (en) 2003-06-18 2010-05-25 Nanobiomagnetics, Inc. Delivery of bioactive substances to target cells
AU2004220325B2 (en) 2003-06-30 2011-05-12 Domantis Limited Polypeptides
EP1649277A2 (de) 2003-07-14 2006-04-26 Environmental Security Corporation Verteilter sensor-array zur überwachung von flüssigkeitskontaminationen
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
CA2532837A1 (en) 2003-07-18 2005-04-21 Baxter International, Inc. Method for preparing small spherical particles by controlled phase separation
DE10355904A1 (de) 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
WO2005067971A1 (ja) * 2004-01-16 2005-07-28 Takeda Pharmaceutical Company Limited 動脈硬化の予防・治療用医薬
CA2553104A1 (en) 2004-01-23 2005-08-11 Avi Biopharma, Inc. Antisense oligomers and methods for inducing immune tolerance and immunosuppression
BRPI0507608A (pt) 2004-02-12 2007-07-03 Merck Patent Gmbh formulações de anticorpos anti-egfr lìquidas altamente concentradas
ATE409025T1 (de) * 2004-05-12 2008-10-15 Baxter Int Nukleinsäure-mikrokügelchen, ihre herstellung und abgabe
MXPA06012989A (es) * 2004-05-12 2007-06-12 Baxter Int Microesferas de acidos nucleicos, produccion y suministro de las mismas.
CA2564791A1 (en) 2004-06-14 2005-12-29 Medimmune Vaccines, Inc. High pressure spray-dry of bioactive materials
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
WO2006072527A1 (de) 2005-01-05 2006-07-13 Siemens Aktiengesellschaft Head-up-display für ein kraftfahrzeug
JP4595112B2 (ja) 2005-02-14 2010-12-08 独立行政法人産業技術総合研究所 タンパク質の高効率分離または濃縮方法
CA2604840A1 (en) 2005-04-18 2006-10-26 Xtl Biopharmaceuticals Ltd. Stabilized anti-hepatitis b (hbv) antibody formulations
RU2303833C2 (ru) 2005-07-26 2007-07-27 Самсунг Электро-Меканикс Ко., Лтд. Осветительное устройство
CN101378782A (zh) 2005-12-21 2009-03-04 惠氏公司 粘度降低的蛋白质制剂及其用途

Also Published As

Publication number Publication date
EP1765294B1 (de) 2008-09-24
EP2335689A1 (de) 2011-06-22
ES2422757T3 (es) 2013-09-13
EP2072040A1 (de) 2009-06-24
AU2005244842B2 (en) 2010-09-23
ES2313350T3 (es) 2009-03-01
US9339465B2 (en) 2016-05-17
JP2011256203A (ja) 2011-12-22
US20060018971A1 (en) 2006-01-26
ATE409025T1 (de) 2008-10-15
EP2072040B1 (de) 2013-05-01
DK2072040T3 (da) 2013-07-29
CA2566079A1 (en) 2005-12-01
US20110033551A1 (en) 2011-02-10
MXPA06012990A (es) 2007-02-12
JP2007537284A (ja) 2007-12-20
DK1765294T3 (da) 2008-11-10
AU2005244842A1 (en) 2005-12-01
EP1765294A1 (de) 2007-03-28
PT1765294E (pt) 2008-12-30
WO2005112894A1 (en) 2005-12-01
US7815941B2 (en) 2010-10-19

Similar Documents

Publication Publication Date Title
DE602005009954D1 (de) Nukleinsäure-mikrokügelchen, ihre herstellung und abgabe
CN107663377B (zh) 一种具有温敏和光敏特性的混合水凝胶及其3d打印方法
ATE374598T1 (de) Mikropartikel und verfahren zur deren herstellung
CN103435706B (zh) 淀粉纳米微球的制备方法
BR0301253A (pt) Microesferas poliméricas em emulsão / agregação para aplicações biomédicas e processos de produção das mesmas
DE60104340D1 (de) Verfahren zur Herstellung von wirkstofbeladenen Polymer-Micellen Zusammensetzung
ATE284676T1 (de) Herstellung von wirkstoffpartikeln durch evaporation-präzipitation in wässrige lösungen
EP1726299A3 (de) Kerne und Mikrokapsel zur parenteralen Verabreichung sowie Verfahren zu deren Herstellung
CN104945847B (zh) 一种环氧树脂纳米微胶囊及其制备方法
CN103272544B (zh) 对温度/pH双敏感的核-壳型覆盆子状智能复合微球及制备方法
CN110193007A (zh) 一种pH响应型水凝胶的制备方法及其应用
ATE438385T1 (de) Pharmazeutische zusammensetzung
CN105111526A (zh) 一种层状硅酸盐/天然胶乳复合胶膜及其制备方法
CN105017551A (zh) 一种表面改性聚合物中空微球、其制备方法及应用
CN107057611A (zh) 一种聚丙烯酸类水凝胶黏合剂的制备方法
CN109895468A (zh) 一种可降解易印刷包装膜及其生产方法
CN106757785A (zh) 一种载银壳聚糖/聚乙烯醇微米带及其制备方法与应用
CN108727576A (zh) 一种能发射多色荧光的超支化聚氨基酯及制备方法
ATE514746T1 (de) Kohlenstoffnanoröhrchen verstärkte polymerzusammensetzung und verfahren zu deren herstellung
CN101792149A (zh) 球状二氧化硅空心材料及其制备方法
FI20040741A0 (fi) Pigmentti ja täyteaine sekä menetelmä näiden valmistamiseksi
CN103265710B (zh) 一种微纳米球的制备方法
CN106281187A (zh) 基材与木纹装饰层粘合用pur胶及其生产工艺
CN110189882A (zh) 一种具有蛋白印迹的二氧化碳气体刺激响应磁性纳米材料及其制备方法
CN105061608A (zh) 荧光淀粉纳米晶及其制备方法与应用

Legal Events

Date Code Title Description
8364 No opposition during term of opposition